Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.56 |
| ▸ | SLC27A1 | Q6PCB7 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15026728 | 0.91 | GRM5 (0.46) | GRM5SLC27A1MAPTNPC1ALDH1A1 | |
| SCHEMBL15024355 | 0.87 | GRM5 (0.53) | GRM5ALDH1A1LMNARAB9AKMT2A | |
| SCHEMBL15024242 | 0.87 | GRM5 (0.73) | GRM5MAPTPIK3CGALDH1A1RAB9A | |
| SCHEMBL15024314 | 0.85 | GRM5 (0.42) | GRM5SLC27A1MAPTNPC1ALDH1A1 | |
| SCHEMBL15024393 | 0.85 | GRM5 (0.43) | GRM5ALDH1A1LMNARAB9AKMT2A | |
| SCHEMBL15024458 | 0.85 | GRM5 (0.45) | GRM5NPC1ALDH1A1LMNARAB9A | |
| SCHEMBL15007065 | 0.84 | GRM5 (0.53) | GRM5MAPTALDH1A1LMNARAB9A | |
| SCHEMBL15024344 | 0.84 | PIK3CG (0.45) | GRM5SLC27A1MAPTPIK3CGNPC1 | |
| SCHEMBL15024255 | 0.84 | GRM5 (0.42) | GRM5MAPTALDH1A1LMNATDP1 | |
| SCHEMBL15007038 | 0.84 | GRM5 (0.42) | GRM5MAPTALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642774-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642774-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20130150341-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150341-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150341-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | GRM5 1/4885SLC27A1 1063/4885MAPT 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.